Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)

Recruiting

Phase 3

Iobenguane I-131 & LorlatinibTesting the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)

Sponsor:

Children's Oncology Group

Code:

NCT03126916

Conditions

Ganglioneuroblastoma

Ganglioneuroblastoma, Nodular

Neuroblastoma

Eligibility Criteria

Sex: All

Age: 365 - 30

Healthy Volunteers: Not accepted

Interventions

Autologous Hematopoietic Stem Cell Transplantation

Biospecimen Collection

Bone Marrow Aspiration and Biopsy

Busulfan

Carboplatin

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-10-10. This information was provided to ClinicalTrials.gov by Children's Oncology Group on 2025-10-08.